Table 4.
Types of psychotropic medications prescribed for regular use at each time point
| Week 0 (baseline) | Week 8 | Week 16 | Week 24 | |||||
|---|---|---|---|---|---|---|---|---|
| Control (N = 36) |
Intervention (N = 33) |
Control (N = 28) |
Intervention (N = 29) |
Control (N = 21) |
Intervention (N = 27) |
Control (N = 24) |
Intervention (N = 27) |
|
| Hypnotics and sedativesa | 3 (8.3%) | 6 (18.2%) | 4 (14.3%) | 4 (13.8%) | 3 (14.3%) | 4 (14.8%) | 4 (16.7%) | 2 (7.4%) |
| Benzodiazepinesb | 10 (27.8%) | 13 (39.4%) | 5 (17.9%) | 13 (44.8%) | 3 (14.3%) | 12 (44.4%) | 5 (20.8%) | 9 (33.3%) |
| Antidepressantsc | 21 (58.3%) | 16 (48.5%) | 16 (57.1%) | 11 (37.9%) | 12 (57.1%) | 11 (40.7%) | 14 (58.3%) | 11 (40.7%) |
| Antipsychoticsd | 20 (55.6%) | 16 (48.5%) | 17 (60.7%) | 14 (48.3%) | 12 (57.1%) | 12 (44.4%) | 12 (50.0%) | 12 (44.4%) |
| Anti-dementia drugse | 7 (19.4%) | 6 (18.2%) | 5 (17.9%) | 5 (17.2%) | 2 (9.5%) | 4 (14.8%) | 4 (16.7%) | 5 (18.5%) |
Nmber of people who were prescribed each type of medication for regular use. aAnatomical Therapeutic Chemical (ATC) classification N05C. bATC N05BA, benzodiazepine derivatives classified as anxiolytics. cATC N06A. dATC N05A. eATC N06D